Neuroprotective function of 14-3-3 proteins in neurodegeneration

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Shimada, Tadayuki ^a   Fournier, Alyson E ^b   Yamagata, Kanato ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; PROTEIN 14 3 3;

BRAIN; DEGENERATIVE DISEASE; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW;

14-3-3 PROTEINS; BRAIN; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PROTEIN BINDING; PROTEIN INTERACTION MAPS;

EID: 84893810894     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/564534     Document Type: Review

References (135)

1. Moore B. W., Perez V. J., Carlson F. D., Specific acidic proteins of the nervous system. Physiological and Biochemical Aspects of Nervous Integration 1968 343 360
2. Boston P. F., Jackson P., Thompson R. J., Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. Journal of (Pubitemid 12091513)
3. Berg D., Holzmann C., Riess O., 14-3-3 proteins in the nervous system. Nature Reviews Neuroscience 2003 4 9 752 762 2-s2.0-0141722623 10.1038/nrn1197 (Pubitemid 37280154)
4. Martin H., Patel Y., Jones D., Howell S., Robinson K., Aitken A., Antibodies against the major brain isoforms of 14-3-3 protein. An antibody specific for the N-acetylated amino-terminus of a protein. FEBS Letters 1993 331 3 296 303 2-s2.0-0027371622 10.1016/0014-5793(93)80356-Y (Pubitemid 23287291)
5. Jones D. H., Ley S., Aitken A., Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: implications for function as adapter proteins. FEBS Letters 1995 368 1 55 58 2-s2.0-0029067231 10.1016/0014-5793(95) 00598-4
6. Yaffe M. B., Rittinger K., Volinia S., Caron P. R., Aitken A., Leffers H., Gamblin S. J., Smerdon S. J., Cantley L. C., The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 1997 91 7 961 971 2-s2.0-0031470652 10.1016/S0092-8674(00)80487-0 (Pubitemid 28027829)
7. Obsil T., Ghirlando R., Klein D. C., Ganguly S., Dyda F., Crystal structure of the 14-3-3 ζ:serotonin N-acetyltransferase complex: a role for scaffolding in enzyme regulation. Cell 2001 105 2 257 267 2-s2.0-0035917466 10.1016/S0092-8674(01)00316-6 (Pubitemid 32429515)
8. Tzivion G., Luo Z., Avruch J., A dimeric.14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 1998 394 6688 88 92 2-s2.0-0032474838 10.1038/27938 (Pubitemid 28321808)
9. Fu H., Subramanian R. R., Masters S. C., 14-3-3 Proteins: structure, function, and regulation. Annual Review of Pharmacology and Toxicology 2000 40 617 647 2-s2.0-0034117078 10.1146/annurev.pharmtox.40.1.617 (Pubitemid 30340695)
10. Vincenz C., Dixit V. M., 14-3-3 proteins associate with A20 in an isoform-specific manner and function both as chaperone and adapter molecules. Journal of Biological Chemistry 1996 271 33 20029 20034 2-s2.0-0029829237 10.1074/jbc.271.33.20029 (Pubitemid 26281752)
11. Braselmann S., McCormick F., BCR and RAF form a complex in vivo via 14-3-3 proteins. EMBO Journal 1995 14 19 4839 4848 2-s2.0-0029166558
12. Li F.-Q., Mofunanya A., Harris K., Takemaru K.-I., Chibby cooperates with 14-3-3 to regulate β -catenin subcellular distribution and signaling activity. Journal of Cell Biology 2008 181 7 1141 1154 2-s2.0-46449112475 10.1083/jcb.200709091 (Pubitemid 351923062)
13. Ishida S., Fukazawa J., Yuasa T., Takahashi Y., Involvement of 14-3-3 signaling protein binding in the functional regulation of the transcriptional activator REPRESSION of SHOOT GROWTH by gibberellins. Plant Cell 2004 16 10 2641 2651 2-s2.0-11944253861 10.1105/tpc.104.024604 (Pubitemid 41071352)
14. Ichimura T., Taoka M., Shoji I., Kato H., Sato T., Hatakeyama S., Isobe T., Hachiya N., 14-3-3 proteins sequester a pool of soluble TRIM32 ubiquitin ligase to repress autoubiquitylation and cytoplasmic body formation. Journal of Cell Science 2013 126 2014 2026
15. Umahara T., Uchihara T., Tsuchiya K., Nakamura A., Iwamoto T., Ikeda K., Takasaki M., 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathologica 2004 108 4 279 286 2-s2.0-4844230325 10.1007/s00401-004-0885-4 (Pubitemid 39317695)
16. Sluchanko N. N., Gusev N. B., Oligomeric structure of 14-3-3 protein: what do we know about monomers? FEBS Letters 2012 586 24 4249 4256
17. Freed E., Symons M., Macdonald S. G., McCormick F., Ruggieri R., Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 1994 265 5179 1713 1716 2-s2.0-0028073606 (Pubitemid 24314903)
18. Garcia-Guzman M., Dolfi F., Russello M., Vuori K., Cell adhesion regulates the interaction between the docking protein p130(Cas) and the 14-3-3 proteins. Journal of Biological Chemistry 1999 274 9 5762 5768 2-s2.0-0033605279 10.1074/jbc.274.9.5762 (Pubitemid 29109231)
19. Fanger G. R., Widmann C., Porter A. C., Sather S., Johnson G. L., Vaillancourt R. R., 14-3-3 proteins interact with specific MEK kinases. Journal of Biological Chemistry 1998 273 6 3476 3483 2-s2.0-0032488910 10.1074/jbc.273.6.3476 (Pubitemid 28109768)
20. Leffers H., Madsen P., Rasmussen H. H., Honore B., Andersen A. H., Walbum E., Vandekerckhove J., Celis J. E., Molecular cloning and expression of the transformation sensitive epithelial marker stratifin. A member of a protein family that has been involved in the protein kinase C signalling pathway. Journal of Molecular Biology 1993 231 4 982 998 2-s2.0-0027326971 10.1006/jmbi.1993.1346 (Pubitemid 23209874)
21. Tang S. J., Suen T.-C., McInnes R. R., Buchwald M., Association of the TLX-2 homeodomain and 14-3-3 η signaling proteins. Journal of Biological Chemistry 1998 273 39 25356 25363 2-s2.0-0000040623 10.1074/jbc.273.39.25356 (Pubitemid 28443302)
22. Petosa C., Masters S. C., Bankston L. A., Pohl J., Wang B., Fu H., Liddington R. C., 14-3-3 ζ binds a phosphorylated raf peptide and an unphosphorylated peptide via its conserved amphiphatic groove. Journal of Biological Chemistry 1998 273 26 16305 16310 2-s2.0-0032568665 10.1074/jbc.273.26.16305 (Pubitemid 28311408)
23. Clark G. J., Drugan J. K., Rossman K. L., Carpenter J. W., Rogers-Graham K., Fu H., Der C. J., Campbell S. L., 14-3-3 ζ negatively regulates Raf-1 activity by interactions with the Raf-1 cysteine-rich domain. Journal of Biological Chemistry 1997 272 34 20990 20993 2-s2.0-0030831968 10.1074/jbc.272.34.20990 (Pubitemid 27373953)
24. Yaffe M. B., How do 14-3-3 proteins work? Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Letters 2002 513 1 53 57 2-s2.0-0037138389 10.1016/S0014-5793(01)03288-4 (Pubitemid 34242978)
25. Mackintosh C., Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochemical Journal 2004 381 2 329 342 2-s2.0-3242788127 10.1042/BJ20031332 (Pubitemid 38976512)
26. Aitken A., 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends in Cell Biology 1996 6 9 341 347 2-s2.0-0030248429 10.1016/0962-8924(96)10029-5 (Pubitemid 26283439)
27. Steinacker P., Aitken A., Otto M., 14-3-3 proteins in neurodegeneration. Seminars in Cell and Developmental Biology 2011 22 7 696 704 2-s2.0-80455160307 10.1016/j.semcdb.2011.08.005
28. Foote M., Zhou Y., 14-3-3 proteins in neurological disorders. International Journal of Biochemistry and Molecular Biology 2012 3 2 152 164
29. Colucci M., Roccatagliata L., Capello E., Narciso E., Latronico N., Tabaton M., Mancardi G. L., The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Multiple Sclerosis 2004 10 5 477 481 2-s2.0-4444236122 10.1191/1352458504ms1089oa (Pubitemid 39207217)
30. Hsich G., Kenney K., Gibbs C. J. Jr., Lee K. H., Harrington M. G., The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. New England Journal of Medicine 1996 335 13 924 930 2-s2.0-0029840653 10.1056/NEJM199609263351303 (Pubitemid 26314445)
31. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H. A., Weber T., Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Annals of Neurology 1998 43 1 32 40 2-s2.0-0031914675 10.1002/ana.410430109 (Pubitemid 28124646)
32. Shiga Y., Wakabayashi H., Miyazawa K., Kido H., Itoyama Y., 14-3-3 protein levels and isoform patterns in the cerebrospinal fluid of Creutzfeldt-Jakob disease patients in the progressive and terminal stages. Journal of Clinical Neuroscience 2006 13 6 661 665 2-s2.0-33746010555 10.1016/j.jocn.2005.09.004 (Pubitemid 44066809)
33. Morales D., Skoulakis E. C., Acevedo S. F., 14-3-3s are potential biomarkers for HIV-related neurodegeneration. Journal of Neurovirology 2012 18 5 341 353
34. Fujii K., Tanabe Y., Kobayashi K., Uchikawa H., Kohno Y., Detection of 14-3-3 protein in the cerebrospinal fluid in mitochondrial encephalopathy with lactic acidosis and stroke-like episodes. Journal of the Neurological Sciences 2005 239 1 115 118 2-s2.0-27744548056 10.1016/j.jns.2005.08.007 (Pubitemid 41617424)
35. Siman R., Giovannone N., Toraskar N., Frangos S., Stein S. C., Levine J. M., Kumar M. A., Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage. PLoS ONE 2011 6 12 2-s2.0-83055164442 10.1371/journal.pone.0028938 e28938
36. Goto A., Wang Y.-L., Kabuta T., Setsuie R., Osaka H., Sawa A., Ishiura S., Wada K., Proteomic and histochemical analysis of proteins involved in the dying-back-type of axonal degeneration in the gracile axonal dystrophy (gad) mouse. Neurochemistry International 2009 54 5-6 330 338 2-s2.0-61449148337 10.1016/j.neuint.2008.12.012
37. Siman R., Roberts V. L., McNeil E., Dang A., Bavaria J. E., Ramchandren S., McGarvey M., Biomarker evidence for mild central nervous system injury after surgically-induced circulation arrest. Brain Research 2008 1213 1 11 2-s2.0-44449140131 10.1016/j.brainres.2008.03.034
38. Cookson M. R., Bandmann O., Parkinson's disease: insights from pathways. Human Molecular Genetics 2010 19 1 R21 R27 2-s2.0-77953890085 10.1093/hmg/ddq167
39. Hughes A. J., Ben-Shlomo Y., Daniel S. E., Lees A. J., What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992 42 6 1142 1146 2-s2.0-0026629509
40. Braak H., Del Tredici K., Rüb U., De Vos R. A. I., Jansen Steur E. N. H., Braak E., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003 24 2 197 211 2-s2.0-0037333666 10.1016/S0197-4580(02)00065-9 (Pubitemid 36007810)
41. Jellinger K. A., Formation and development of Lewy pathology: a critical update. Journal of Neurology 2009 256 3 S270 S279 2-s2.0-69549116777 10.1007/s00415-009-5243-y
42. Lücking C. B., Brice A., Alpha-synuclein and Parkinson's disease. Cellular and Molecular Life Sciences 2000 57 13-14 1894 1908 2-s2.0-0034489853 (Pubitemid 32102585)
43. Iwata A., Maruyama M., Kanazawa I., Nukina N., α -synuclein affects the MAPK pathway and accelerates cell death. Journal of Biological Chemistry 2001 276 48 45320 45329 2-s2.0-0035976959 10.1074/jbc.M103736200
44. Perez R. G., Waymire J. C., Lin E., Liu J. J., Guo F., Zigmond M. J., A role for α -synuclein in the regulation of dopamine biosynthesis. Journal of Neuroscience 2002 22 8 3090 3099 2-s2.0-0037092442 (Pubitemid 35379198)
45. Singleton A. B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M. R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K., α -synuclein locus triplication causes Parkinson's disease. Science 2003 302 5646 841 2-s2.0-0242300619 10.1126/science.1090278 (Pubitemid 37339619)
46. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T. E., Muzyczka N., Mandel R. J., Björklund A., Parkinson-like neurodegeneration induced by targeted overexpression of α -synuclein in the nigrostriatal system. Journal of Neuroscience 2002 22 7 2780 2791 2-s2.0-0036550101 (Pubitemid 37465827)
47. Yacoubian T. A., Slone S. R., Harrington A. J., Hamamichi S., Schieltz J. M., Caldwell K. A., Caldwell G. A., Standaert D. G., Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson's disease. Cell Death and Disease 2010 1 1, article e2 2-s2.0-77952216305 10.1038/cddis.2009.4
48. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V., Greenamyre J. T., Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 2000 3 12 1301 1306 2-s2.0-0033681149 10.1038/81834
49. Kawamoto Y., Akiguchi I., Nakamura S., Honjyo Y., Shibasaki H., Budka H., 14-3-3 Proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. Journal of Neuropathology and Experimental Neurology 2002 61 3 245 253 2-s2.0-0036196220 (Pubitemid 34212599)
50. Berg D., Riess O., Bornemann A., Specification of 14-3-3 proteins in Lewy bodies. Annals of Neurology 2003 54 1 135 2-s2.0-0038462211 (Pubitemid 36764993)
51. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B., α -synuclein shares physical and functional homology with 14-3-3 proteins. Journal of Neuroscience 1999 19 14 5782 5791 2-s2.0-0033565874 (Pubitemid 29327915)
52. Xu J., Kao S.-Y., Lee F. J. S., Song W., Jin L.-W., Yankner B. A., Dopamine-dependent neurotoxicity of α -synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nature Medicine 2002 8 6 600 606 2-s2.0-0036278335 10.1038/nm0602-600 (Pubitemid 34633438)
53. Sato S., Chiba T., Sakata E., Kato K., Mizuno Y., Hattori N., Tanaka K., 14-3-3 η is a novel regulator of parkin ubiquitin ligase. EMBO Journal 2006 25 1 211 221 2-s2.0-30444448687 10.1038/sj.emboj.7600774 (Pubitemid 43077309)
54. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S. J., Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996 87 4 619 628 2-s2.0-0030584088 10.1016/S0092-8674(00)81382-3 (Pubitemid 26386936)
55. Nomura M., Shimizu S., Sugiyama T., Narita M., Ito T., Matsuda H., Tsujimoto Y., 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. Journal of Biological Chemistry 2003 278 3 2058 2065 2-s2.0-0037449733 10.1074/jbc.M207880200 (Pubitemid 36801450)
56. Slone S. R., Lesort M., Yacoubian T. A., 14-3-3theta protects against neurotoxicity in a cellular parkinson's disease model through inhibition of the apoptotic factor Bax. PLoS ONE 2011 6 7 2-s2.0-79960607222 10.1371/journal.pone. 0021720 e21720
57. 2+calmodulin-dependent protein kinase II. FEBS Letters 1987 219 1 79 82 2-s2.0-0023652643
58. Wang J., Lou H., Pedersen C. J., Smith A. D., Perez R. G., 14-3-3 ζ contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. Journal of Biological Chemistry 2009 284 21 14011 14019 2-s2.0-67649804671 10.1074/jbc.M901310200
59. Toska K., Kleppe R., Armstrong C. G., Morrice N. A., Cohen P., Haavik J., Regulation of tyrosine hydroxylase by stress-activated protein kinases. Journal of Neurochemistry 2002 83 4 775 783 2-s2.0-0036847425 10.1046/j.1471-4159.2002. 01172.x (Pubitemid 35316027)
60. Shimura H., Hattori N., Kubo S.-I., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T., Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics 2000 25 3 302 305 2-s2.0-0033933048 10.1038/77060 (Pubitemid 30437317)
61. Kahle P. J., Haass C., How does parkin ligate ubiquitin to Parkinson's disease? First in molecular medicine review series. EMBO Reports 2004 5 7 681 685 2-s2.0-4444370179 10.1038/sj.embor.7400188 (Pubitemid 39173002)
62. Paisán-Ruíz C., Jain S., Evans E. W., Gilks W. P., Simón J., Van Der Brug M., De Munain A. L., Aparicio S., Gil A. M., Khan N., Johnson J., Martinez J. R., Nicholl D., Carrera I. M., Peňa A. S., De Silva R., Lees A., Martí-Massó J. F., Pérez-Tur J., Wood N. W., Singleton A. B., Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004 44 4 595 600 2-s2.0-8844266996 10.1016/j.neuron.2004.10.023 (Pubitemid 39531224)
63. Nichols R. J., Dzamko N., Morrice N. A., Campbell D. G., Deak M., Ordureau A., Macartney T., Tong Y., Shen J., Prescott A. R., Alessi D. R., 14-3-3 Binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochemical Journal 2010 430 3 393 404 2-s2.0-77956674229 10.1042/BJ20100483
64. Li X., Wang Q. J., Pan N., Lee S., Zhao Y., Chait B. T., Yue Z., Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial parkinson's disease. PLoS ONE 2011 6 3 2-s2.0-79952302007 10.1371/journal.pone.0017153 e17153
65. Dzamko N., Deak M., Hentati F., Reith A. D., Prescott A. R., Alessi D. R., Nichols R. J., Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. Biochemical Journal 2010 430 3 405 413 2-s2.0-77956655427 10.1042/BJ20100784
66. Fraser K. B., Moehle M. S., Daher J. P., LRRK2 secretion in exosomes is regulated by 14-3-3. Human Molecular Genetics 2013
67. Tucci A., Nalls M. A., Houlden H., Revesz T., Singleton A. B., Wood N. W., Hardy J., Paisán-Ruiz C., Genetic variability at the PARK16 locus. European Journal of Human Genetics 2010 18 12 1356 1359 2-s2.0-78549251699 10.1038/ejhg.2010.125
68. MacLeod D. A., Rhinn H., Kuwahara T., RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 2013 77 3 425 439
69. Rowland L. P., Shneider N. A., Amyotrophic lateral sclerosis. New England Journal of Medicine 2001 344 22 1688 1700 2-s2.0-0035978743 10.1056/NEJM200105313442207 (Pubitemid 32479968)
70. Strong M. J., Kesavapany S., Pant H. C., The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? Journal of Neuropathology and Experimental Neurology 2005 64 8 649 664 2-s2.0-23844538993 (Pubitemid 41177106)
71. Lee M. K., Xu Z., Wong P. C., Cleveland D. W., Neurofilaments are obligate heteropolymers in vivo. Journal of Cell Biology 1993 122 6 1337 1350 2-s2.0-0027293898 (Pubitemid 23277302)
72. Lariviere R. C., Julien J.-P., Functions of intermediate filaments in neuronal development and disease. Journal of Neurobiology 2004 58 1 131 148 2-s2.0-0348011603 10.1002/neu.10270 (Pubitemid 37543344)
73. Wong N. K. Y., He B. P., Strong M. J., Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). Journal of Neuropathology and Experimental Neurology 2000 59 11 972 982 2-s2.0-0033763630
74. Volkening K., Leystra-Lantz C., Yang W., Jaffee H., Strong M. J., Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Research 2009 1305 168 182 2-s2.0-73949134014 10.1016/j.brainres.2009.09.105
75. Ge W.-W., Volkening K., Leystra-Lantz C., Jaffe H., Strong M. J., 14-3-3 protein binds to the low molecular weight neurofilament (NFL) mRNA 3′ UTR. Molecular and Cellular Neuroscience 2007 34 1 80 87 2-s2.0-33845900214 10.1016/j.mcn.2006.10.001 (Pubitemid 46026930)
76. Kawamoto Y., Akiguchi I., Nakamura S., Budka H., 14-3-3 proteins in Lewy body-like hyaline inclusions in patients with sporadic amyotrophic lateral sclerosis. Acta Neuropathologica 2004 108 6 531 537 2-s2.0-8844250806 10.1007/s00401-004-0923-2 (Pubitemid 39534595)
77. Tan C.-F., Eguchi H., Tagawa A., Onodera O., Iwasaki T., Tsujino A., Nishizawa M., Kakita A., Takahashi H., TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathologica 2007 113 5 535 542 2-s2.0-34247606414 10.1007/s00401-007-0206-9 (Pubitemid 46672599)
78. Okamoto Y., Shirakashi Y., Ihara M., Urushitani M., Oono M., Kawamoto Y., Yamashita H., Shimohama S., Kato S., Hirano A., Tomimoto H., Ito H., Takahashi R., Colocalization of 14-3-3 proteins with SOD1 in Lewy body-like hyaline inclusions in familial amyotrophic lateral sclerosis cases and the animal model. PLoS ONE 2011 6 5 2-s2.0-79957874613 10.1371/journal.pone.0020427 e20427
79. Miao L., Teng J., Lin J., Liao X., 14-3-3 proteins interact with neurofilament protein-L and regulate dynamic assembly of neurofilaments. Journal of Cell Science 2013 126 427 436
80. Namikawa K., Su Q., Kiryu-Seo S., Kiyama H., Enhanced expression of 14-3-3 family members in injured motoneurons. Molecular Brain Research 1998 55 2 315 320 2-s2.0-0032052689 10.1016/S0169-328X(98)00012-6 (Pubitemid 28248048)
81. Malaspina A., Kaushik N., De Belleroche J., A 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal cord. Journal of Neurochemistry 2000 75 6 2511 2520 2-s2.0-0033777919 10.1046/j.1471-4159.2000.0752511.x
82. Hu J.-H., Zhang H., Wagey R., Krieger C., Pelech S. L., Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. Journal of Neurochemistry 2003 85 2 432 442 2-s2.0-0345184327 (Pubitemid 36438338)
83. Kent C. B., Shimada T., Ferraro G. B., Ritter B., Yam P. T., McPherson P. S., Charron F., Kennedy T. E., Fournier A. E., 14-3-3 proteins regulate protein kinase A activity to modulate growth cone turning responses. Journal of Neuroscience 2010 30 42 14059 14067 2-s2.0-77958591710 10.1523/JNEUROSCI.3883- 10.2010
84. Lee V. M.-Y., Disruption of the cytoskeleton in Alzheimer's disease. Current Opinion in Neurobiology 1995 5 5 663 668 2-s2.0-0028894984 10.1016/0959-4388(95)80073-5
85. Alonso A. D. C., Zaidi T., Grundke-Iqbal I., Iqbal K., Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America 1994 91 12 5562 5566 2-s2.0-0028227962 10.1073/pnas.91.12.5562 (Pubitemid 24174368)
86. Yuan Z., Agarwal-Mawal A., Paudel H. K., 14-3-3 Binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3 β in the brain. Journal of Biological Chemistry 2004 279 25 26105 26114 2-s2.0-2942755865 10.1074/jbc.M308298200 (Pubitemid 38798755)
87. Agarwal-Mawal A., Qureshi H. Y., Cafferty P. W., Yuan Z., Han D., Lin R., Paudel H. K., 14-3-3 Connects glycogen synthase kinase-3 β to tau within a brain microtubule-associated tau phosphorylation complex. Journal of Biological Chemistry 2003 278 15 12722 12728 2-s2.0-0037631324 10.1074/jbc.M211491200 (Pubitemid 36800034)
88. Sadik G., Tanaka T., Kato K., Yamamori H., Nessa B. N., Morihara T., Takeda M., Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. Journal of Neurochemistry 2009 108 1 33 43 2-s2.0-57249108291 10.1111/j.1471-4159.2008. 05716.x
89. Busser J., Geldmacher D. S., Herrup K., Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. Journal of Neuroscience 1998 18 8 2801 2807 2-s2.0-0032522911 (Pubitemid 28163210)
90. Yang Y., Geldmacher D. S., Herrup K., DNA replication precedes neuronal cell death in Alzheimer's disease. Journal of Neuroscience 2001 21 8 2661 2668 2-s2.0-0035871660 (Pubitemid 32298208)
91. Moh C., Kubiak J. Z., Bajic V. P., Zhu X., Smith M. A., Lee H.-G., Cell cycle deregulation in the neurons of Alzheimer's disease. Results and Problems in Cell Differentiation 2011 53 565 576 2-s2.0-79959685557 10.1007/978-3-642- 19065-0-23
92. Lee K.-Y., Clark A. W., Rosales J. L., Chapman K., Fung T., Johnston R. N., Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neuroscience Research 1999 34 1 21 29 2-s2.0-0032988741 10.1016/S0168-0102(99) 00026-7 (Pubitemid 29245996)
93. Vincent I., Bu B., Hudson K., Husseman J., Nochlin D., Jin L.-W., Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease. Neuroscience 2001 105 3 639 650 2-s2.0-0035881867 10.1016/S0306-4522(01)00219-6 (Pubitemid 32769828)
94. Chang K. H., Vincent F., Shah K., Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. Journal of Cell Science 2012 125 21 5124 5137
95. Jang S.-W., Liu X., Fu H., Rees H., Yepes M., Levey A., Ye K., Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. Journal of Biological Chemistry 2009 284 36 24512 24525 2-s2.0-69949167523 10.1074/jbc.M109.026237
96. Hong Y., Chan C. B., Kwon I. S., SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer's disease. Journal of Neuroscience 2012 32 48 17262 17272
97. Yuan Z., Becker E. B. E., Merlo P., Yamada T., DiBacco S., Konishi Y., Schaefer E. M., Bonni A., Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 2008 319 5870 1665 1668 2-s2.0-41149160386 10.1126/science.1152337 (Pubitemid 351432504)
98. Will R. G., Epidemiology of Creutzfeldt-Jakob disease. British Medical Bulletin 1993 49 4 960 977 2-s2.0-0027716662
99. Špero M., Lazibat I., Creutzfeldt-Jakob disease: case report and review of the literature. Acta Clinica Croatica 2010 49 2 181 187 2-s2.0-78149351457
100. Kenny K., Brechtel C., Takahashi H., Kurohara K., Anderson P., Gibbs C. J. Jr., An enzyme-linked immunosorbent assay to quantify 14-3-3 proteins in the cerebrospinal fluid of suspected Creutzfeldt-Jakob disease patients. Annals of Neurology 2000 48 3 395 398
101. Richard M., Biacabe A.-G., Streichenberger N., Ironside J. W., Mohr M., Kopp N., Perret-Liaudet A., Immunohistochemical localization of 14.3.3 ζ protein in amyloid plaques in human spongiform encephalopathies. Acta Neuropathologica 2003 105 3 296 302 2-s2.0-0038790332 (Pubitemid 36798823)
102. Orr H. T., Chung M.-Y., Banfi S., Kwiatkowski T. J. Jr., Servadio A., Beaudet A. L., McCall A. E., Duvick L. A., Ranum L. P. W., Zoghbi H. Y., Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nature Genetics 1993 4 3 221 226 2-s2.0-0027164698 10.1038/ng0793-221 (Pubitemid 23205168)
103. Robitaille Y., Schut L., Kish S. J., Structural and immunocytochemical features of olivopontocerebellar atrophy caused by the spinocerebellar ataxia type 1 (SCA-1) mutation define a unique phenotype. Acta Neuropathologica 1995 90 6 572 581 2-s2.0-0028832215 10.1007/s004010050371
104. Zoghbi H. Y., Orr H. T., Spinocerebellar ataxia type 1. Seminars in Cell and Developmental Biology 1995 6 1 29 35 2-s2.0-0029245258
105. Irwin S., Vandelft M., Pinchev D., Howell J. L., Graczyk J., Orr H. T., Truant R., RNA association and nucleocytoplasmic shuttling by ataxin-1. Journal of Cell Science 2005 118 1 233 242 2-s2.0-14044266141 10.1242/jcs.01611 (Pubitemid 40277118)
106. Arrasate M., Mitra S., Schweitzer E. S., Segal M. R., Finkbeiner S., Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004 431 7010 805 810 2-s2.0-7244236320 10.1038/nature02998 (Pubitemid 39434070)
107. Bowman A. B., Lam Y. C., Jafar-Nejad P., Chen H.-K., Richman R., Samaco R. C., Fryer J. D., Kahle J. J., Orr H. T., Zoghbi H. Y., Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes. Nature Genetics 2007 39 3 373 379 2-s2.0-33847290297 10.1038/ng1977 (Pubitemid 46328494)
108. Lai S., O'Callaghan B., Zoghbi H. Y., Orr H. T., 14-3-3 Binding to ataxin-1(ATXN1) regulates its dephosphorylation at Ser-776 and transport to the nucleus. Journal of Biological Chemistry 2011 286 40 34606 34616 2-s2.0-80053405457 10.1074/jbc.M111.238527
109. Jafar-Nejad P., Ward C. S., Richman R., Orr H. T., Zoghbi H. Y., Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3 ε haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America 2011 108 5 2142 2147 2-s2.0-79952168998 10.1073/pnas. 1018748108
110. Jou Y.-S., Myers R. M., Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Human Molecular Genetics 1995 4 3 465 469 2-s2.0-0028904293
111. Kaneko K., Hachiya N. S., The alternative role of 14-3-3 zeta as a sweeper of misfolded proteins in disease conditions. Medical Hypotheses 2006 67 1 169 171 2-s2.0-33646097228 10.1016/j.mehy.2006.01.019
112. Omi K., Hachiya N. S., Tanaka M., Tokunaga K., Kaneko K., 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Neuroscience Letters 2008 431 1 45 50 2-s2.0-38049080224 10.1016/j.neulet.2007.11.018
113. Henshall D. C., Simon R. P., Epilepsy and apoptosis pathways. Journal of Cerebral Blood Flow and Metabolism 2005 25 12 1557 1572 2-s2.0-28044450402 10.1038/sj.jcbfm.9600149 (Pubitemid 41683168)
114. Schindler C. K., Shinoda S., Simon R. P., Henshall D. C., Subcellular distribution of Bcl-2 family proteins and 14-3-3 within the hippocampus during seizure-induced neuronal death in the rat. Neuroscience Letters 2004 356 3 163 166 2-s2.0-0442323501 10.1016/j.neulet.2003.11.048 (Pubitemid 38186677)
115. Schindler C. K., Heverin M., Henshall D. C., Isoform- and subcellular fraction-specific differences in hippocampal 14-3-3 levels following experimentally evoked seizures and in human temporal lobe epilepsy. Journal of Neurochemistry 2006 99 2 561 569 2-s2.0-33749162349 10.1111/j.1471-4159.2006. 04153.x (Pubitemid 44477211)
116. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K.-I., Takeda K., Minowa O., Miyazono K., Noda T., Ichijo H., ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Reports 2001 2 3 222 228 2-s2.0-0035065836 10.1093/embo-reports/kve046 (Pubitemid 32273301)
117. Shinoda S., Skradski S. L., Araki T., Schindler C. K., Meller R., Lan J.-Q., Taki W., Simon R. P., Henshall D. C., Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death. European Journal of Neuroscience 2003 17 10 2065 2076 2-s2.0-0037795559 10.1046/j.1460-9568.2003.02655.x (Pubitemid 36713967)
118. Zhang Q.-G., Han D., Xu J., Lv Q., Wang R., Yin X.-H., Xu T.-L., Zhang G.-Y., Ischemic preconditioning negatively regulates plenty of SH3s-mixed lineage kinase 3-Rac1 complex and c-Jun N-terminal kinase 3 signaling via activation of Akt. Neuroscience 2006 143 2 431 444 2-s2.0-33750826785 10.1016/j.neuroscience.2006.07.049 (Pubitemid 44716587)
119. Fan J., Xu G., Nagel D. J., Hua Z., Zhang N., Yin G., A model of ischemia and reperfusion increases JNK activity, inhibits the association of BAD and 14-3-3, and induces apoptosis of rabbit spinal neurocytes. Neuroscience Letters 2010 473 3 196 201 2-s2.0-77950339995 10.1016/j.neulet.2010.02.045
120. Murry C. E., Jennings R. B., Reimer K. A., Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986 74 5 1124 1136 2-s2.0-0022970945 (Pubitemid 17174962)
121. Yang C., Ren Y., Liu F., Cai W., Zhang N., Nagel D. J., Yin G., Ischemic preconditioning suppresses apoptosis of rabbit spinal neurocytes by inhibiting ASK1-14-3-3 dissociation. Neuroscience Letters 2008 441 3 267 271 2-s2.0-47249087218 10.1016/j.neulet.2008.06.037
122. Yang X., Luo C., Cai J., Pierce W. M., Tezel G., Phosphorylation- dependent interaction with 14-3-3 in the regulation of bad trafficking in retinal ganglion cells. Investigative Ophthalmology and Visual Science 2008 49 6 2483 2494 2-s2.0-47249120101 10.1167/iovs.07-1344
123. Wenning G. K., Ben Shlomo Y., Magalhães M., Daniel S. E., Quinn N. P., Clinical features and natural history of multiple system atrophy: an analysis of 100 cases. Brain 1994 117 4 835 845 2-s2.0-0027930620 (Pubitemid 24281844)
124. Papp M. I., Kahn J. E., Lantos P. L., Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). Journal of the Neurological Sciences 1989 94 1-3 79 100 2-s2.0-0024843373 10.1016/0022-510X(89) 90219-0 (Pubitemid 20019446)
125. Nakazato Y., Yamazaki H., Hirato J., Ishida Y., Yamaguchi H., Oligodendroglial microtubular tangles in olivopontocerebellar atrophy. Journal of Neuropathology and Experimental Neurology 1990 49 5 521 530 2-s2.0-0025173009 (Pubitemid 20264006)
126. Wakabayashi K., Yoshimoto M., Tsuji S., Takahashi H., α -synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neuroscience Letters 1998 249 2-3 180 182 2-s2.0-0032546895 10.1016/S0304- 3940(98)00407-8 (Pubitemid 28331545)
127. Gai W. P., Power J. H. T., Blumbergs P. C., Blessing W. W., Multiple-system atrophy: a new α -synuclein disease? The Lancet 1998 352 9127 547 548 2-s2.0-0032529707 10.1016/S0140-6736(05)79256-4 (Pubitemid 28372254)
128. Fellner L., Stefanova N., The role of glia in alpha-synucleinopathies. Molecular Neurobiology 2013 47 2 575 586
129. Kawamoto Y., Akiguchi I., Nakamura S., Budka H., Accumulation of 14-3-3 proteins in glial cytoplasmic inclusions in multiple system atrophy. Annals of Neurology 2002 52 6 722 731 2-s2.0-0036896686 10.1002/ana.10361 (Pubitemid 35403181)
130. Compston A., Coles A., Multiple sclerosis. The Lancet 2002 359 9313 1221 1231 2-s2.0-0037029424 10.1016/S0140-6736(02)08220-X (Pubitemid 34304266)
131. Satoh J.-I., Yamamura T., Arima K., The 14-3-3 protein ε isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. American Journal of Pathology 2004 165 2 577 592 2-s2.0-3242749629 (Pubitemid 38971387)
132. Eliasson C., Sahlgren C., Berthold C.-H., Stakeberg J., Celis J. E.,
133. Inagaki M., Nakamura Y., Takeda M., Nishimura T., Inagaki N., Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation. Brain Pathology 1994 4 3 239 243 2-s2.0-0028100397 (Pubitemid 24261930)
134. Domercq M., Brambilla L., Pilati E., Marchaland J., Volterra A., Bezzi P., P2Y1 receptor-evoked glutamate exocytosis from astrocytes: control by tumor necrosis factor- α and prostaglandins. Journal of Biological Chemistry 2006 281 41 30684 30696 2-s2.0-33750052586 10.1074/jbc.M606429200 (Pubitemid 44582124)
135. Brambilla R., Bracchi-Ricard V., Hu W.-H., Frydel B., Bramwell A., Karmally S., Green E. J., Bethea J. R., Inhibition of astroglial nuclear factor B reduces inflammation and improves functional recovery after spinal cord injury. Journal of Experimental Medicine 2005 202 1 145 156 2-s2.0-22344431751 10.1084/jem.20041918 (Pubitemid 41002917)